Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: blood transfusion Clear all
Completed No phase listed Observational

Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion

NCT07290634
View directory record Official record
Conditions
Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma
Interventions
Number of Participants with massive blood transfusion
Procedure
Lead sponsor
Zeliha Alicikus
Government
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 8:12 AM EDT
Terminated Phase 3 Interventional

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

NCT00654433
View directory record Official record
Conditions
Inherited Metabolic Diseases, Lysosomal Storage Disorders, Peroxisomal Storage Diseases, Inborn Errors of Metabolism, Mucopolysaccharidosis
Interventions
ALD-101
Biological
Lead sponsor
Aldagen
Industry
Eligibility
Up to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Early Phase 1 Interventional Results available

COVID-19 Convalescent Plasma

NCT04340050
View directory record Official record
Conditions
Coronavirus
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 15, 2026, 8:12 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

NCT00981370
View directory record Official record
Conditions
Anemia, Sickle Cell, Transfusion Hemosiderosis
Interventions
deferasirox
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Not applicable Interventional

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

NCT05634005
View directory record Official record
Conditions
Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
Interventions
Clinical Decision Support
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adverse Effects of RBC Transfusions: A Unifying Hypothesis

NCT00838331
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fresh blood, Aged blood
Biological
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 15, 2026, 8:12 AM EDT
Not listed Phase 1Phase 2 Interventional

Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO

NCT02851472
View directory record Official record
Conditions
Anemia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
New York Medical College
Other
Eligibility
2 Weeks and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Springfield, Massachusetts • Stony Brook, New York • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Placental Transfusion in Term Infants: A Pilot Study

NCT01924572
View directory record Official record
Conditions
Anemia
Interventions
cord clamping at 2 minutes, cord clamping at 5 minutes, cord milking
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 15, 2026, 8:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Phosphorylated Tau Levels in Donated Blood

NCT07157839
View directory record Official record
Conditions
Alzheimer&Amp;#39;s Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01829503
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
decitabine and cytarabine, Supportive Care
Drug · Other
Lead sponsor
Annie Im, M.D.
Other
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

NCT00067080
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 1 Interventional

Red Cell Transfusion Goals in Patients With Acute Leukemias

NCT02086773
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Acute Promyelocytic Leukemia (APL)
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

NCT01362595
View directory record Official record
Conditions
Diamond Blackfan Anemia, Blackfan Diamond Syndrome, DBA, Congenital Hypoplastic Anemia, Pure Red Cell Aplasia
Interventions
leucine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Palo Alto, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 15, 2026, 8:12 AM EDT
Not yet recruiting Phase 2 Interventional

Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs

NCT07152379
View directory record Official record
Conditions
Transfusion Reaction, Hemolytic
Interventions
30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

NCT02483702
View directory record Official record
Conditions
Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions
Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
2 Months to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 15, 2026, 8:12 AM EDT
Recruiting Not applicable Interventional

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

NCT03204357
View directory record Official record
Conditions
Cardiac Disease, Bleeding Postoperative
Interventions
Fresh Autologous whole Blood, Standard of Care Expectant management of bleeding
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 15, 2026, 8:12 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00840827
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
lenalidomide, cyclosporine A
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

NCT00098280
View directory record Official record
Conditions
Hemoglobinuria, Paroxysmal
Interventions
Eculizumab
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 8:12 AM EDT
Completed Not applicable Interventional Results available

A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty

NCT01285024
View directory record Official record
Conditions
Arthritis
Interventions
Vitagel
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 15, 2026, 8:12 AM EDT
Recruiting Phase 2 Interventional

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

NCT04143724
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ACE-536
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 8:12 AM EDT
Completed No phase listed Observational Results available

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

NCT05340751
View directory record Official record
Conditions
Anesthesia
Interventions
Blood drawn
Diagnostic Test
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
40 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 15, 2026, 8:12 AM EDT
Terminated Not applicable Interventional Results available

The Benefits of a Preoperative Anemia Management Program

NCT01888003
View directory record Official record
Conditions
Anemia, Iron-Deficiency
Interventions
Iron sucrose, Epoetin Alfa, Blood Transfusion
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 15, 2026, 8:12 AM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 15, 2026, 8:12 AM EDT